Medication info
Rosuvastatin Calcium Tablet 10 mg

Rosuvastatin Calcium Tablet 10 mg

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Seohung Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201906607 · Approved 2019.09.23 · Insurance code 679601220

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, reduction of cardiovascular disease risk
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.
Children's dosage
Aged 10 years to 17 years: The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Seohung Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, reduction of cardiovascular disease risk

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used as an adjunct to diet and exercise in the treatment of hyperlipidemia when primary hypercholesterolemia and mixed hyperlipidemia cannot be adequately controlled. It is also suitable as an adjunct treatment for patients with homozygous familial hypercholesterolemia. It lowers total cholesterol and LDL cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis. It is used to reduce cholesterol and Apo-B levels in pediatric patients aged between 10 and 17 years with heterozygous familial hypercholesterolemia. In addition, it is effective as an adjunct to diet in patients with primary dysbetalipoproteinemia, and helps reduce the risk of stroke, myocardial infarction, and arterial revascularization in adults with a high risk of cardiovascular disease. Overall, this medication is used for various forms of hyperlipidemia and to reduce the risk of cardiovascular disease.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.

Children's dosage

Aged 10 years to 17 years: The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, it is contraindicated in patients who are allergic to this medication, have severe liver dysfunction, muscle disorders, and severe kidney impairment. Special caution is needed when administering this medication to women who are pregnant, breastfeeding, or of childbearing age without appropriate contraception. It should only be used if the risk to the fetus is well explained and if there is a low possibility of pregnancy. The use of high doses of this medication is contraindicated in patients at high risk of muscle-related side effects, such as patients with moderate to severe renal impairment, hypothyroidism, or alcohol dependence. Since this medication contains lactose, patients with lactose intolerance or specific genetic metabolic disorders should avoid it. Patients who consume alcohol excessively or have a history of liver disease should undergo liver function tests before taking this medication and regularly check liver enzyme levels during treatment. Muscle pain, myopathy, and, rarely, severe muscle damage such as rhabdomyolysis may occur, so patients should immediately consult a physician if abnormal muscle symptoms arise, and blood tests should be performed to assess muscle damage. In cases of acute renal failure or severe conditions, this medication should be discontinued, and it should also be stopped if muscle weakness or ocular muscle weakness develops. Interactions may occur when used in combination with other drugs, especially with fibrates or certain antiviral agents, antifungals, and antibiotics, which may increase the risk of muscle side effects. Because the plasma concentration of this medication may be higher in Asians, dose adjustment may be necessary. In pediatric patients, the effects on growth and secondary sexual characteristics have been limitedly evaluated, so it should be used cautiously in children. This medication may rarely cause various side effects including liver dysfunction, skin rash, headache, dizziness, gastrointestinal symptoms, so any abnormal symptoms should be reported to healthcare professionals. This medication should not be used during pregnancy or breastfeeding, and women planning to become pregnant should use appropriate contraception. In case of overdose, there is no specific antidote, so symptomatic treatment and monitoring liver function and muscle enzymes are required. Caution is needed as dizziness may occur while driving or operating machinery. During the course of treatment, liver function, muscle status, and blood tests if necessary should be continuously monitored for safety.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, abnormal liver function test, syncope, widespread pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air or moisture, so it should be stored in a tightly closed container. Additionally, it is best stored at room temperature between 1 degree and 30 degrees Celsius. Storing it this way helps maintain the effectiveness of the medication.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.